期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

TRAIL在膀胱移行细胞癌的表达与预后关系 被引量：2

Correlation of TRAIL expression with prognosis of bladder transitional cell carcinoma
下载PDF
导出
摘要 目的检测膀胱移行细胞癌(BTCC)和正常膀胱组织中肿瘤坏死因子相关凋亡诱导配体(TRAIL)的表达,探讨TRAIL表达与BTCC预后的关系。方法免疫组化Elivision法检测76例BTCC和15例正常膀胱组织病理标本中TRAIL的表达;结合临床病理学资料分析其之间的相关性。结果76例BTCC病理标本中有45例(59.21%)TRAIL阴性表达,G2、G3组的TRAIL阴性表达率(68.63%)明显高于G1组(40.00%,P<0.05);肿瘤多发组中TRAIL阴性表达率(75.86%)明显高于单发组(48.94%,P<0.05)。log-rank test分析TRAIL表达阴性组与阳性组间无复发生存率有统计学意义(P<0.05),TRAIL阴性表达组的无复发生存时间(33.65月)明显低于阳性表达组(46.49月)。结论TRAIL在BTCC中表达下调,且与BTCC数目、分级、复发相关,可作为判断BTCC预后的参考指标。 Objective To determine expression of tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) in bladder transitional cell carcinoma(BTCC) and normal bladder tissues and to explore the correlation among TRAIL and clinico-pathological parameters and prognosis of BTCC.Methods TRAIL protein expression was determined by immunohistochemistry assay(Elivision).Results TRAIL negative expression was shown in 45(59.21%) of the 76 cases of BTCC,and it was higher in poorly differentiated(G2,G3) tumors than in wel...
作者 甄洪涛 张怀强 许复郁 萧畔
机构地区 山东大学第二医院泌尿外科 山东大学第二医院病理科
出处 《山东大学学报（医学版）》 CAS 北大核心 2009年第1期61-63,67,共4页 Journal of Shandong University:Health Sciences
关键词 肿瘤坏死因子相关凋亡诱导配体 膀胱移行细胞癌 基因表达 预后 Tumor necrosis factor-related apoptosis-inducing ligand Bladder transitional cell carcinoma Gene expression Prognosis
分类号 R737.14 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献22

  • 1蔡明江,殷玉华,姬秋和,张南雁,黄威权.促性腺素释放激素受体与凋亡相关蛋白FAS在前列腺肿瘤中的共表达及意义[J].解剖学杂志,2004,27(3):263-265. 被引量：1
  • 2Wiley SR, Schooley K,Smolak PJ,et al. Identification and characterization of a New Member of the TNF family that induces Apoptosin. Immunity, 1995,3:673-682
  • 3Fukuda M, Hammao A, Tanaka A, et al. Tumor necrosis factor-related apoptosio-inducing ligand(TRAIL/Apo2L) and its receptors expression in Human squamons all carcinoma of the oral cavity. Oncol Rep, 2003,10(5):1113-1119
  • 4Schally AV,Comaru Schally AM.Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions.Adu Drug Deliv Rev,1997,28(1):157-169
  • 5Comaru Schally AM,Brannan W,Schally AV,et al. Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.J Clin Endocrinol metab,1998,83(11):3826-3831
  • 6Marsters SA, Pitti RA,Sheridan JP, et al. Control of apoptosis signaling by APO-2 ligand. Recent Prog Horm Res,1999,54:225-234
  • 7Hu WH, Johnson H, Shu HB, ET AL.Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathway. J Biol Chem,1999,274(43):30603
  • 8Kin KH, Fisher MJ, Xu SQ, et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clinical Cancer Research, 2000, 6: 335-346
  • 9Jean-Luc Buder, Holler N , Rieser E , et al. TRAIL receptor-2signals apoptosis through FADD AND caspase-8 [ J ]. Nat Cell Biol, 2000, 2(2) :241-243.
  • 10Thomas WD, Zhang XD, Franco AV, et al. TNF-related apoptosis-inducing ligand-indced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of nitochondria [ J ]. Immunology, 2000 , 165(10) :5612-5620.

共引文献118

同被引文献16

  • 1王金,徐祗顺,史本康,刘玉强,徐中华,辛健,陈军.应用钬激光腔内治疗泌尿系疾病53例报告[J].山东大学学报（医学版）,2006,44(6):648-648. 被引量：1
  • 2Chopin D K, Gattegno B. Superficial bladder tumors[J]. Eur Url, 2002, 42 ( 6). 1075-1078.
  • 3Soler M J, V C R, M-Jimenez P, et al. Holmium laser treatment for cow grade, low stage, noninvasive bladder cancer with local anesthesia and early instillation of mitomycin C[J]. J Urol, 2007, 178(6) :2337-2339.
  • 4Kim S I, Kwon S M, Kim Y S, et al. Association of cyclonxygenase-2 expression with prognosisofstageT, grade3bladder cancer [ J ]. Urology, 2002, 60 ( 7 ) : 816- 821.
  • 5Wang KM, Yang J, Huang Y, et al. The expression of bcl - 2 and bax proteins in gastricoma and precancerous lesions [ J ]. J Xi "an Med Univ ,2001,13 ( 1 ) :56 - 58.
  • 6Popnikolov NK, Gatalica Z, Adegboyega PA, et al. Downregulation of TNF - related apoptosis - inducing ligand ( TRAIL )/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma [ J ]. Appl Immunohistochem Mol Morpho1,2006 ,14 (2) : 161 - 165.
  • 7Vigneswaran N, Baucum DC, Wu J, et al. Repression of tumor nec- rosis factor related apoptosis - inducing ligand(TRAIL) but not its receptors during oral cancer progression [ J ]. BMC Cancer,2007,25 (7) :108.
  • 8Mariani SM, Krammer PH. Surface expression of TRAIL/Apo - 2 ligand in activated mouse T and B cell [ J]. Eur J Immunol, 1998, 28 ( 11 ) : 1492 - 1498.
  • 9Robert MP, Scot AM, Siegfrie DR, et al. Induction of apoptosis by Apo -2 ligand a new member of the tumor necrosis factor cytosive family [ J ]. Biol Chem, 1996,271 (22) : 12678.
  • 10Secchierro P, Zerbinati C, Di Iasio MG, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non - genotoxic activator of the p53 pathway nuflin -3 in acute myeloid leukemia ceils [J]. Curt Drug Metab,2007,8(4) :395 -403.

引证文献2

山东大学学报（医学版）
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部